Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival drug ...
Pfizer's BENEGENE-2 study met its primary endpoint of non-inferiority and superiority ... (RMAT), as well as orphan drug designation by the FDA and PRIority Medicines (PRIME) and orphan drug ...
International Investment's unique blend of content for the international wealth management community is now available exclusively on Investment Week. International Investment formerly served ...
Alnylam's RNAi TTR Silencing Drug Amvuttra FDA Approved for Transthyretin Amyloidosis Cardiomyopathy
The drug was already sold for TTR amyloidosis with polyneuropathy, and now is available to patients with hereditary or wild-type ATTR-CM.
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions ...
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback